Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy With or Without SBRT for Oligometastatic Pancreatic Cancer
NCT04975516Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jul 2023
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2023; status: terminated.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04975516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975516.